NFKB1 and Alzheimer disease: Specifically, the use of IL‐38 in AD to reduce the expression of pro‐inflammatory IL‐1β and TNF‐α and inhibit the NF‐κB/BACE1 signaling axis is an interesting direction for future study (Figure 2).33